Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease.

Hu Y, Hosseini A, Kauwe JS, Gross J, Cairns NJ, Goate AM, Fagan AM, Townsend RR, Holtzman DM.

Proteomics Clin Appl. 2007 Nov;1(11):1373-84. doi: 10.1002/prca.200600999. Epub 2007 Oct 16.

PMID:
21136637
2.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

3.

Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease.

Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, Bhuvanendran S, Fenz KM, Strickland S.

Neuron. 2010 Jun 10;66(5):695-709. doi: 10.1016/j.neuron.2010.05.014.

4.

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Jun;119(6):669-78. doi: 10.1007/s00401-010-0667-0. Epub 2010 Mar 16.

5.

The role of macrophage migration inhibitory factor in Alzheimer's disease.

Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R.

Mol Med. 2010 Mar;16(3-4):116-21. doi: 10.2119/molmed.2009.00123. Epub 2010 Feb 28.

6.

Cystatin C protects neuronal cells from amyloid-beta-induced toxicity.

Tizon B, Ribe EM, Mi W, Troy CM, Levy E.

J Alzheimers Dis. 2010;19(3):885-94. doi: 10.3233/JAD-2010-1291.

7.

Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients.

Cheng X, Yang L, He P, Li R, Shen Y.

J Alzheimers Dis. 2010;19(2):621-30. doi: 10.3233/JAD-2010-1253.

8.

Sparse partial least squares regression for simultaneous dimension reduction and variable selection.

Chun H, Keleş S.

J R Stat Soc Series B Stat Methodol. 2010 Jan;72(1):3-25.

9.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

10.

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM.

EMBO Mol Med. 2009 Nov;1(8-9):371-80. doi: 10.1002/emmm.200900048.

11.

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.

Perrin RJ, Fagan AM, Holtzman DM.

Nature. 2009 Oct 15;461(7266):916-22. doi: 10.1038/nature08538. Review.

12.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

13.

Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2.

Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, Mullan M, Paris D.

J Neurochem. 2010 Jan;112(1):66-76. doi: 10.1111/j.1471-4159.2009.06426.x. Epub 2009 Oct 10.

14.

The FAS gene, brain volume, and disease progression in Alzheimer's disease.

Erten-Lyons D, Jacobson A, Kramer P, Grupe A, Kaye J.

Alzheimers Dement. 2010 Mar;6(2):118-24. doi: 10.1016/j.jalz.2009.05.663. Epub 2009 Sep 18.

15.

Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia.

Ban Y, Watanabe T, Suguro T, Matsuyama TA, Iso Y, Sakai T, Sato R, Idei T, Nakano Y, Ota H, Miyazaki A, Kato N, Hirano T, Ban Y, Kobayashi Y.

J Atheroscler Thromb. 2009 Jun;16(3):179-87.

16.

Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.

Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O.

PLoS One. 2009 Jul 17;4(7):e6294. doi: 10.1371/journal.pone.0006294.

17.

Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.

Bürger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, Yafai Y, Schliebs R.

Int J Dev Neurosci. 2009 Oct;27(6):517-23. doi: 10.1016/j.ijdevneu.2009.06.011. Epub 2009 Jul 7.

PMID:
19589380
18.

Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease.

Leyhe T, Hoffmann N, Stransky E, Laske C.

Int J Neuropsychopharmacol. 2009 Nov;12(10):1319-26. doi: 10.1017/S1461145709990216. Epub 2009 Jul 7.

PMID:
19580698
19.

VEGF genetic variability is associated with increased risk of developing Alzheimer's disease.

Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP.

J Neurol Sci. 2009 Aug 15;283(1-2):66-8. doi: 10.1016/j.jns.2009.02.318. Epub 2009 Mar 9.

PMID:
19272614
20.

Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.

Fabbro S, Seeds NW.

J Neurochem. 2009 Apr;109(2):303-15. doi: 10.1111/j.1471-4159.2009.05894.x. Epub 2009 Feb 13.

Supplemental Content

Support Center